DEDIFFERENTIATED LEIOMYOSARCOMA
DOI:
https://doi.org/10.30649/obj.v6i2.130Kata Kunci:
Kata Kunci : leiomyosarcoma, pleomorphic, dedifferentiatedAbstrak
ABSTRAK
LATAR BELAKANG : Leiomyosarkoma (LMS) adalah sarkoma jaringan lunak agresif yang berkisar antara 7-10% dari semua kasus sarkoma jaringan lunak, biasanya terjadi pada pasien dewasa dan lanjut usia.
LAPORAN KASUS : Pasien Tn. M, pria, 71 tahun, buruh bangunan, Kabupaten Tulungagung. Pasien memiliki keluhan utama yaitu terdapat benjolan di bawah ketiak kanan, dirasakan sejak 2 bulan sebelum berkunjung ke RSUD dr. Iskak Tulungagung.
DISKUSI : Pleomorphic LMS atau dedifferentiated LMS menunjukkan gambaran pleomorfisme nonspesifik dan berdiferensiasi buruk. Untuk menegakkan diagnosis ini, gambaran morfologi yang khas dari LMS klasik harus didapatkan, atau pasien harus memiliki riwayat LMS sebelumnya. Pada pemeriksaan imunohistokimia, sekitar 50-75% dari pleomorphic LMS bersifat positif untuk setidaknya satu penanda miogenik, meskipun pulasannya seringkali bersifat lemah dan lebih fokal daripada pada area tipikal leiomyosarkoma.
KESIMPULAN : Gambaran morfologi dedifferentiated LMS secara mikroskopik dapat menyerupai gambaran sarkoma derajat tinggi lainnya, sehingga diperlukan pertimbangan klinis, radiologis, histopatologi serta pemeriksaan lanjutan seperti pulasan immunohistokimia.
Referensi
Huntoon, K., Toland, A.M.S., and Dahiya, S. 2020. Meningioma: A Review of Clinicopathological and Molecular Aspects. Front. Oncol. 10, 579599.
Ostrom, Q.T.; Cioffi, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; et al. 2019. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 21, v1–v100.
Lassie, N. dan Supartoto, A. 2016. Progesterone Receptor Expression in Histopathological Subtypes of Beningn Orbitocranial Meningiomas. Ophthalmol Ina, 42(1), 91–96.
Zhao, L., Zhao, W., Hou, Y., Wen, C., Wang, J., Wu, P., et al. 2020. An Overview of Managements in Meningiomas. Frontiers in Oncology, 10 (August), 1–12. https://doi.org/10.3389/fonc.2020.01523.
Ozek, E., Ozcan, D., Celik, S. E., and Iplikcioglu, A. C. 2018. Matrix metalloprotease-9 expresssion in meningioma: Correlation with growth fraction and role of gender. A pilot immunohistochemical study. Clinical Neurology and Neurosurgery, 172, 169–173. https://doi.org/10.1016/j.clineuro.2018.07.002.
Baldi, I., Engelhardt, J., Bonnet, C., Bauchet, L., Berteaud, E., Grüber, A., et al, Epidemiology of meningiomas, Neuro-Chirurgie (2014), https://doi.org/10.1016/j. neuchi.2014.05.006.
Apriyani, V. 2021. Faktor Risiko Meningioma Orbitokranial Pada Wanita Pengguna Kontrasepsi Hormonal. Tesis. Tidak diterbitkan, Fakultas Kedokteran Universitas Padjajaran Bandung.
Lee, Y.S. Molecular Characteristics of Meningiomas. J. Pathol. Transl. Med. 2020;54:45–63. doi: 10.4132/jptm.2019.11.05.
Louis, D.N., Ohgaki, H., Wiestler, O.D., and Cavenee, W.K. WHO Classification of Tumours of the Central Nervous System; World Health Organization Classification of Tumours. 4th ed. International Agency for Research on Cancer; Lyon, France: 2016.
Perry, A, Meningioma. In: Perry A, Brat DJ, eds. Practical Surgical Neuropathology: A Diagnostic Approach. 2nd edition. Philadelphia: Elsevier; 2018:259–298.
Mnango, L., Mwakimonga, A., Ngaiza, A., Yahaya, J.J., Vuhahula, E., and Mwakigonja, A.R. 2021. Expression of Progesterone Receptor and Its Association with Clinicopathological Characteristics in Meningiomas: A Cross-Sectional Study. World Neurosurg X. Jul 14;12:100111. doi: 10.1016/j.wnsx.2021.100111. PMID: 34401742; PMCID: PMC8355943.
Hsu D.W., Efird J.T., Hedley-Whyte E.T. Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg. 1997;86:113–120.
Roser F., Nakamura M., Bellinzona M., Rosahl S.K., Ostertag H., Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol. 2004;57:1033–1037.
Shayanfar N, Mashayekh M, Mohammadpour M. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma. Acta Med Iran. 2010 May-Jun;48(3):142-7. PMID: 21137648.
Kunimatsu A., Kunimatsu N., Kamiya K., Katsura M., Mori H., Ohtomo K. Variants of meningiomas: a review of imaging findings and clinical features. Jpn J Radiol. 2016;34:459–469.
Ramos-Vara, J.A. et al. (2014) ‘Immunohistochemical Evaluation of the Effects of Paraffin Section Storage on Biomarker Stability’, Veterinary Pathology, 51(1), pp. 102–109. Available at: https://doi.org/10.1177/0300985813476067.
Backer-Grøndahl, T., Moen, B.H., Arnli, M.B., Torseth, K., and Torp, S.H. 2014. Immunohistochemical characterization of brain-invasive meningiomas. International Journal of Clinical and Experimental Pathology, 7(10), pp. 7206–7219.
Barresi, V., Alafaci, C., Caffo, M., Barresi, G., and Tuccari, G. 2012. Clinicopathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas. Pathology Research and Practice, 208(6), pp. 350–355. Available at: https://doi.org/10.1016/j.prp.2012.02.013.
Reszec, J., Hermanowicz, A., Rutkowski, R., Turek, G., Mariak, Z., and Chyczewski, L. Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int. 2015; 2015:646853. doi: 10.1155/2015/646853. Epub 2015 Mar 3. PMID: 25821815; PMCID: PMC4363610.
Elhakeem, A.A.E., Essa, A.A., Soliman, R.K. Hamdan, A.R.K. Novel evaluation of the expression patterns CD44 and MMP9 proteins in intracranial meningiomas and their relationship to the overall survival. 2022. Egypt J Neurosurg 37, 33. https://doi.org/10.1186/s41984-022-00173-x.
Barresi, V., Alafaci, C., Caffo, M., Barresi, G., and Tuccari, G. 2012. Clinicopathological characteristics, hormone receptor status and matrix metallo-proteinase-9 (MMP-9) immunohistochemical expression in spinal meningiomas. Pathology Research and Practice, 208(6), pp. 350–355. Available at: https://doi.org/10.1016/j.prp.2012.02.013.
Wang, X., Zhang, J., Yang, Y., Dong, W., Wang, F., Wang, L., et al. 2013. Progesterone attenuates cerebral edema in neonatal rats with hypoxic-ischemic brain damage by inhibiting the expression of matrix metalloproteinase-9 and aquaporin-4. Experimental and Therapeutic Medicine, 6(1), 263–267. https://doi.org/10.3892/etm.2013.1116.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Oceana Biomedicina Journal
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
